Apellis Pharmaceuticals Inc. (APLS) stock soared 5.07% in Tuesday's intraday trading session, outperforming the broader market.
The rally in APLS shares came after JP Morgan maintained its "Overweight" rating on the biopharmaceutical company. Analysts at the investment bank reiterated their positive stance on Apellis, likely boosting investor confidence in the stock.